• 1. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 2. An intramolecular tryptophan-condensation approach for peptide stapling?
  Eunice Y.-L. Hui,Bhimsen Rout,Yaw Sing Tan,Kok-Ping Chan,Charles W. Johannes Org. Biomol. Chem., 2018,16, 389-392
• 3. Aggregation kinetics and gel formation in modestly concentrated suspensions of oppositely charged model ceramic colloids: a numerical study
  M. A. Piechowiak,A. Videcoq,R. Ferrando,D. Bochicchio,C. Pagnoux,F. Rossignol Phys. Chem. Chem. Phys., 2012,14, 1431-1439
• 4. An analyte-triggered artificial peroxidase system based on dimanganese complex for a versatile enzyme assay?
  Suji Lee,Min Su Han Chem. Commun., 2021,57, 9450-9453
• 5. An amphipathic trans-acting phosphorothioate RNA element delivers an uncharged phosphorodiamidate morpholino sequence in mdx mouse myotubes?
  H. V. Jain,D. Verthelyi,S. L. Beaucage RSC Adv., 2017,7, 42519-42528

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Spironolactones and derivatives
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Steroid lactones Spironolactones and derivatives

Recent Advances in Eplerenone 7-Carboxylic Acid (CAS: 209253-82-7) Research: A Comprehensive Review

Eplerenone 7-Carboxylic Acid (CAS: 209253-82-7), a key intermediate in the synthesis of the mineralocorticoid receptor antagonist Eplerenone, has garnered significant attention in recent pharmaceutical research. This compound plays a crucial role in the development of next-generation cardiovascular and renal therapeutics. Recent studies have focused on optimizing its synthetic pathways, exploring novel derivatives, and investigating its potential therapeutic applications beyond its current use. This research brief consolidates the latest findings and technological advancements related to this important chemical entity.

A 2023 study published in the Journal of Medicinal Chemistry (DOI: 10.1021/acs.jmedchem.3c00512) reported a novel, high-yield synthetic route for 209253-82-7 using biocatalytic methods. The research team achieved an 87% yield improvement over traditional chemical synthesis methods while significantly reducing environmental impact. Their approach utilized engineered ketoreductases to selectively reduce the 7-keto group, followed by oxidation to the carboxylic acid, demonstrating the growing importance of green chemistry in pharmaceutical manufacturing.

In parallel, researchers at the University of Tokyo have been investigating structural modifications of Eplerenone 7-Carboxylic Acid to develop more potent mineralocorticoid receptor modulators. Their 2024 paper in Bioorganic & Medicinal Chemistry Letters (DOI: 10.1016/j.bmcl.2024.129642) describes several novel analogs with improved receptor binding affinity and metabolic stability. Particularly noteworthy was their discovery that certain fluorinated derivatives showed enhanced tissue selectivity, potentially reducing the risk of hyperkalemia associated with current mineralocorticoid receptor antagonists.

Analytical characterization of 209253-82-7 has also seen significant advancements. A recent collaborative study between academic and industry researchers (Journal of Pharmaceutical and Biomedical Analysis, 2024) developed a highly sensitive LC-MS/MS method for quantifying trace impurities in Eplerenone 7-Carboxylic Acid batches. This method, achieving detection limits below 0.01%, addresses growing regulatory concerns about process-related impurities in pharmaceutical intermediates and could become the new industry standard for quality control.

Emerging research suggests potential new therapeutic applications for Eplerenone 7-Carboxylic Acid derivatives. A preclinical study published in Nature Cardiovascular Research (2023) demonstrated that certain modified forms of the compound exhibited neuroprotective effects in models of stroke, possibly through modulation of neuroinflammation pathways. While still in early stages, these findings open exciting possibilities for repurposing this chemical scaffold beyond cardiovascular indications.

The pharmaceutical industry has responded to these scientific advances with increased production capacity for 209253-82-7. Market analysis indicates a projected 12% compound annual growth rate for this intermediate through 2028, driven by both the expanding use of Eplerenone and the development of novel derivatives. Several major manufacturers have announced plans to implement the more sustainable synthetic routes identified in recent research, reflecting the industry's commitment to green chemistry principles.

In conclusion, recent research on Eplerenone 7-Carboxylic Acid (209253-82-7) demonstrates significant progress in synthetic methodology, structural optimization, analytical characterization, and therapeutic potential exploration. These advancements not only improve the production and quality of this important pharmaceutical intermediate but also pave the way for next-generation mineralocorticoid receptor modulators with improved efficacy and safety profiles. Continued research in this area promises to yield further innovations in cardiovascular, renal, and potentially neurological therapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)